NKTR icon

Nektar Therapeutics

0.7407 USD
-0.0151
2.00%
At close Apr 29, 4:00 PM EDT
After hours
0.7230
-0.0177
2.39%
1 day
-2.00%
5 days
8.93%
1 month
8.93%
3 months
-11.52%
6 months
-41.68%
Year to date
-22.92%
1 year
-49.27%
5 years
-96.24%
10 years
-92.69%
 

About: Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Employees: 61

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

4,260% more call options, than puts

Call options by funds: $218K | Put options by funds: $5K

40% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 15

36% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 36

4% more funds holding

Funds holding: 139 [Q3] → 145 (+6) [Q4]

4.6% less ownership

Funds ownership: 76.64% [Q3] → 72.04% (-4.6%) [Q4]

32% less capital invested

Capital invested by funds: $183M [Q3] → $124M (-$59.3M) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$2
170%
upside
Avg. target
$4.83
553%
upside
High target
$6.50
778%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Jefferies
Roger Song
16% 1-year accuracy
3 / 19 met price target
170%upside
$2
Buy
Upgraded
11 Apr 2025
Oppenheimer
Jay Olson
20% 1-year accuracy
16 / 80 met price target
710%upside
$6
Outperform
Upgraded
14 Mar 2025
HC Wainwright & Co.
Arthur He
9% 1-year accuracy
3 / 32 met price target
778%upside
$6.50
Buy
Reiterated
13 Mar 2025

Financial journalist opinion

Negative
Zacks Investment Research
2 weeks ago
Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report?
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?
Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report?
Neutral
PRNewsWire
1 month ago
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
SAN FRANCISCO , March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference: H.C.
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Negative
Zacks Investment Research
1 month ago
Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)
Nektar Therapeutics (NKTR) came out with quarterly loss of $0.15 per share, missing the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.
Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)
Negative
Zacks Investment Research
1 month ago
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up
NKTR fourth-quarter earnings and revenues lag estimates. 2025 is poised to be a catalyst year for rezpeg, with multiple data readouts expected.
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up
Neutral
Zacks Investment Research
1 month ago
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Nektar (NKTR) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say
Positive
Zacks Investment Research
1 month ago
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Nektar (NKTR) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say
Neutral
Seeking Alpha
1 month ago
Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript
Nektar Therapeutics (NASDAQ:NKTR ) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Company Participants Vivian Wu - Investor Relations Howard Robin - President & Chief Executive Officer Brian Kotzin - Interim Chief Medical Officer Jonathan Zalevsky - Chief Research & Development Officer Sandra Gardiner - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Julian Harrison - BTIG Jay Olson - Oppenheimer Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Arthur He - H.C.
Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript
Neutral
PRNewsWire
1 month ago
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash and investments in marketable securities on December 31, 2024 were $269.1 million as compared to $329.4 million at December 31, 2023.
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Neutral
PRNewsWire
1 month ago
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets
SAN FRANCISCO , March 5, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2024 on Wednesday, March 12, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m.
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets
Neutral
PRNewsWire
2 months ago
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata
SAN FRANCISCO , Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata. Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells (Tregs).
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata
Charts implemented using Lightweight Charts™